A Drug Delivery Strategy: Binding Enkephalin to Asialoglycoprotein Receptor by Enzymatic Galactosylation

Author
Christie, Michelle P., Simerska, Pavla, Jen, Freda, M. Hussein, Waleed, F. M. Rawi, Mohamad, Hartley-Tassell, Lauren, Day, Christopher, Jennings, Michael, Toth, Istvan

Published
2014

Journal Title
PloS One

DOI
https://doi.org/10.1371/journal.pone.0095024

Copyright Statement
Copyright 2014 Christie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Downloaded from
http://hdl.handle.net/10072/67439
A Drug Delivery Strategy: Binding Enkephalin to Asialoglycoprotein Receptor by Enzymatic Galactosylation

Michelle P. Christie¹, Pavla Simerská¹, Freda E.-C. Jen², Waleed M. Hussein¹, Mohamad F. M. Rawi¹, Lauren E. Hartley-Tassell², Christopher J. Day², Michael P. Jennings², Istvan Toth¹,³*

Introduction

The clinical use of peptide-based therapeutics is mainly limited by their poor membrane permeability and stability in biological systems. Different strategies have been used to improve the physico-chemical characteristics of peptides to make them more amenable as therapeutics [1,2]. These include chemical modifications such as cyclization and peptide bond reduction [3], use of unnatural amino acids [4,5], co-administration with penetration enhancers such as bile salts and surfactants [6], and conjugation with bacterial and viral proteins [7], lipids [8,9], and carbohydrates [10–12].

The coupling of carbohydrate moieties such as glucose or lactose to peptides improved their solubility, stability and permeability [13–17]. Additionally, glycosylation enhanced bioavailability and passage through the blood brain barrier [18–20]. The addition of carbohydrates can also enable cellular uptake via sugar transporters [11,21] and may be used to target specific cells via carbohydrate receptors [17,22]. The transport of glucose and galactose across the intestinal membranes occurs primarily via the sodium-glucose co-transporter 1 (SGLT1) or the facilitated diffusion glucose transporter protein 2 (GLUT2) [23]. Although these transporters are primarily responsible for the transport of sugars, some studies have implicated them in the movement of other carbohydrate-modified compounds such as glycopeptides [11,19,21].

Several studies used carbohydrate receptor binding to target drug molecules, DNA and peptides to specific cells types [17,22,24,25]. In this study, we focused on the asialoglycoprotein receptor (ASGPR) located on hepatic cells [26] and in discrete areas of the brain, such as the cerebellum and brain stem [27]. ASGPR belongs to the C-type lectin family [28] and is targeted by glycoproteins and liposaccharides that contain terminal galactose or N-acetylgalactosamine, for example asialoorosomucoid [29] and gonococcal lipoooligosaccharide [30,31].

Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) is an opioid peptide with known pain-regulating activity and the potential to be used as a therapeutic when delivered to the central nervous system. Several previous attempts have been made to improve the delivery of enkephalin to the central nervous system, including lipidation [8,9] and glycosylation [9,32]. Various glycosyltransferases were found to be an efficient tool for the addition of carbohydrate moieties such as glucose or lactose to peptides improved their solubility, stability and permeability [13–17]. Additionally, glycosylation enhanced bioavailability and passage through the blood brain barrier [18–20]. The addition of carbohydrates can also enable cellular uptake via sugar transporters [11,21] and may be used to target specific cells via carbohydrate receptors [17,22]. The transport of glucose and galactose across the intestinal membranes occurs primarily via the sodium-glucose co-transporter 1 (SGLT1) or the facilitated diffusion glucose transporter protein 2 (GLUT2) [23]. Although these transporters are primarily responsible for the transport of sugars, some studies have implicated them in the movement of other carbohydrate-modified compounds such as glycopeptides [11,19,21].

Several studies used carbohydrate receptor binding to target drug molecules, DNA and peptides to specific cells types [17,22,24,25]. In this study, we focused on the asialoglycoprotein receptor (ASGPR) located on hepatic cells [26] and in discrete areas of the brain, such as the cerebellum and brain stem [27]. ASGPR belongs to the C-type lectin family [28] and is targeted by glycoproteins and liposaccharides that contain terminal galactose or N-acetylgalactosamine, for example asialoorosomucoid [29] and gonococcal lipoooligosaccharide [30,31].
moieties to biologically active peptides [33–35]. We previously galactosylated the enkephalin peptide chemically by solid phase peptide synthesis and enzymatically using galactosyltransferase as described by Simerska et al. [35].

The main aim of this study was to examine the ability of the glycosylated compounds $N^1$-Leu-enkephalin-$N^4$-(β-D-galactopyranosyl)succinamide (Gal-Enk), $N^1$-Leu-enkephalin-$N^4$-(β-D-galactopyranosyl-1→4)-β-D-glucopyranosyl)succinamide (Lac-Enk) and $N^1$-Leu-enkephalin-$N^4$-(α-D-galactopyranosyl-1→4)-β-D-galactopyranosyl-1→4)-β-D-galactopyranosyl)succinamide (Gal-Lac-Enk) to bind to the carbohydrate receptor ASGPR. First, we performed a one-pot enzymatic reaction for the synthesis of Gal-Lac-Enk catalyzed by uridine-5'-diphosphogalactose 4-epimerase (EC 5.1.3.2; galactose epimerase) and lipopolysaccharide-1,4-galactosyltransferase (EC 2.4.1.; LgtC) using uridine-5'-diphosphate-α-D-glucose (UDP-Glc) and Lac-Enk as substrates (Figure 1). The stability and permeability of the carbohydrate-conjugated enkephalins was tested in vitro using Caco-2 cells. Finally, the binding of glycosylated-enkephalins to immobilized ASGPR was assessed using surface plasmon resonance (SPR) experiments and molecular docking.

**Experimental Section**

**Materials**

All chemicals were of analytical grade or equivalent (unless otherwise stated) and purchased from EMD (Darmstadt, Germany), Mimotopes (Clayton, Australia), Merck (Kilsyth, Australia), Sigma-Aldrich (Castle-Hill, Australia), UniV (Ingleburn, Australia), Scharlau (Port Adelaide, Australia), Grand Island Biological Company (GIBCO, Mulgrave, Australia), CalBioChem (Darmstadt, Germany), Rink Amide 4-methyl benzhydryl amine (Rink Amide-MBHA) was from Peptides International, USA. TALON resin used for the purification of LgtC enzyme was from Clontech (Mountain View, USA). Galactose epimerase was from Sigma Aldrich (Castle-Hill, Australia) and UDP-Glc and uridine-5'-diphosphate-α-D-galactose (UDP-Gal) was from CalBioChem (Darmstadt, Germany).

Analytical reversed phase high performance liquid chromatography (RP-HPLC) was conducted on Shimadzu Instrumentation (Kyoto, Japan) with LabSolutions software, SIL-20AC HT autosampler, LC-20AB pump, SPD-M10A detector and a DGU-20A5 degasser. Either an Alltima C18 column (5 m, 4.6 mm × 250 mm; Grace Davison Discovery Sciences, Deerfield, USA) or a Grace Vydac C18 column (10 m, 4.6 mm × 250 mm; Grace Davison Discovery Sciences, Deerfield, USA) was used. Solvent A was 0.1% trifluoroacetic acid (TFA) in water and solvent B was 90% acetonitrile (ACN)/water/0.1% TFA. Samples were run for 30 min at a flow rate of 1 mL/min with detection at 214 nm.

Preparative RP-HPLC was conducted on a Waters Delta 600 system (Milford, USA) at a flow rate of 20 mL/min and detection at 230 nm using PicoLog software. A Vydac C18 column (10 m, 22 mm × 250 mm; Grace Davison Discovery Sciences, Deerfield, USA) was used for all purifications.

Electrospray ionization mass spectrometry (ES-MS) and liquid chromatography mass spectrometry (LC-MS) were conducted on a Perkin-Elmer-Sciex API 3000 mass spectrometer (Applied Biosystems/MDS Sciex, Toronto, Canada). Solvents used for ES-MS and LC-MS consisted of solvent A: 0.1% acetic acid.
(AcOH) in water and solvent B: 90% ACN/10% water/0.1%
AcOH. A Phenomenex Luna C18 column (5
µm, 50 x 2.0 mm, Torrance, USA) was used for LC-MS analysis. Instrument control,
data acquisition, and data analysis were carried out using Analyst
software version 1.4.1. (Applied Biosystems/MDS Sciex, Toronto,
Canada).

Human colorectal adenocarcinoma cells (Caco-2 cells) were
obtained from the American Type Culture Collection, Rockville,
USA. A Branson Sonifier 250 (Branson Ultrasonics, Danbury,
USA) was used to lyse the cells for stability experiments. Protein
content was measured using the BioRad protein assay kit (BioRad,
Hercules, USA). TPP 96-well plates for stability assays were
purchased from Sigma Aldrich (Castle Hill, Australia). For
permeability studies Caco-2 cell monolayers were grown in 24
well plates with Transwell polycarbonate cell culture inserts (pore
size 0.4 µm, diameter 0.2 mm) from Corning Incorporated (New
York, USA). A Millicell-ERS epithelial Transep volt-ohmmeter
system (EMD Millipore Corporation, Billerica, USA) was used to
measure the transepithelial electrical resistance (TEER) values of
the cells. Scintillation counting was carried out using Liquid
Scintillation Systems from Beckman Coulter (Brea, USA).

SPR experiments were performed on a Biacore T100 (GE
Healthcare, Little Chalfont, UK) at 25°C. Recombinant human
ASGPR (the subunit of ASGPR that contains the carbohydrate
binding site) used was from Sino Biological Inc. (Beijing, China).
The receptor was immobilized onto a series S sensor chip CM5
(GE Healthcare, Little Chalfont, UK) using the
N-hydroxysuccini-
nimide (NHS) capture kit (GE Healthcare, Little Chalfont, UK).

Chemo-enzymatic Synthesis of Enkephalin and its
Glycopeptides

Enkephalin and carbohydrate-modified enkephalins, Gal-Enk,
Lac-Enk and Gal-Lac-Enk, were prepared according to Simerska et al. [35]. Peptides and glycopeptides were assembled using
standard solid phase peptide synthesis on Rink Amide-MBHA
resin using Fmoc chemistry protocols. Crude peptide and
glycopeptides were purified by preparative RP-HPLC, a gradient
of 0–100% solvent B over 60 min was used for enkephalin and a
gradient of 20–35% solvent B over 60 min was used for the
glycosylated enkephalins. Fractions that contained pure peptide/
glycopeptide were analyzed using analytical RP-HPLC and ES-
MS and corresponded with those previously published [35].

The galactosyltransferase LgtC was recombinantly expressed in
Escherichia coli AD202 and purified using TALON metal affinity
resin [35]. The purified protein was dialyzed into 20 mM
Na2HPO4 buffer at pH 7.5, concentrated to 2 mg/mL and stored

Figure 2. Enzymatic transformation of Lac-Enk to Gal-Lac-Enk. A) RP-HPLC analysis of one-pot reaction for Lac-Enk with UDP-Glc and
galactose epimerase. From top to bottom: substrate (Lac-Enk) only; positive control – reaction mixture containing UDP-Gal and LgtC; negative control – reaction mixture containing UDP-Glc and LgtC; reaction mixture containing UDP-Glc, LgtC and galactose epimerase. All reactions were conducted in
50 mM HEPES (pH 7), 10 mM MnCl2 buffer at 37°C. RP-HPLC was conducted on an Altima C18 column using a gradient of 0–90% solvent B, 
tR = 17.2 min (substrate, Lac-Enk) and tR = 16.8 min (product, Gal-Lac-Enk). B) ES-MS analysis of the acceptor, Lac-Enk m/z (C32H52N7O18, 977.4) m/z
978.5 [M+H]+ (calcd. 978.4). C) ES-MS analysis of the product, Gal-Lac-Enk (C52H76N8O23, 1139.5) m/z 1140.5 [M+H]+ (calcd. 1140.5).
doi:10.1371/journal.pone.0095024.g002
in 50% glycerol. One-pot enzyme reaction was performed using 6 mM UDP-Glc (20 μL), and 2 mM Lac-Enk (20 μL) in 20 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid (HEPES) buffer containing 10 mM MnCl₂ at 37°C with 0.2 U (0.015 mg) of galactose epimerase and 1 μL of LgtC (2 mg/mL). The positive control reaction contained 6 mM UDP-Gal (20 μL), and 2 mM Lac-Enk (20 μL) in 20 mM HEPES buffer and 1 μL of LgtC (2 mg/mL), while the negative control contained 6 mM UDP-Glc (20 μL), and 2 mM Lac-Enk (20 μL) in 20 mM HEPES buffer and 1 μL of LgtC (2 mg/mL). An additional 10 μL of UDP-Glc, 0.2 U of galactose epimerase, and 1 μL of LgtC were added to the respective reaction mixtures after 24 hrs. The enzymatic reactions were incubated for a further 24 hrs at 37°C. Reaction progress was followed by RP-HPLC using an Alltima C18 with a gradient of 0–90% solvent B. Gal-Lac-Enk product formation was confirmed by ES-MS (C₅₂H₇₆N₈O₂₃, 1139.5) m/z 1140.5 [M+.

Figure 3. Stability profiles of enkephalin and carbohydrate-derived enkephalins. A) Plasma stability assay: the concentration of compounds in plasma was determined at various time points using RP-HPLC on a C18 Vydac column, gradient of 20–35% (enkephalin) or 0–70% solvent B (glycosylated enkephalins) over 30 min. B) Caco-2 cell stability assay: The concentration of compound in Caco-2 cell homogenates at various time points was quantified using LC-MS. Data presented is the mean ± S.D. (n = 3). doi:10.1371/journal.pone.0095024.g003

Figure 4. Permeability studies of enkephalin and carbohydrate-derived enkephalins. A) Apparent permeability (Pₘₚₚₚₚ (cm/s) of enkephalin and glycosylated enkephalins. (p value <0.05) B) Apparent permeability of enkephalin and glycosylated enkephalin in the presence of the SGLT1 inhibitor phlorizin (horizontal lines) and the GLUT2 inhibitor phloretin (diagonal lines). Pₘₚₚₚₚ values in the presence of inhibitor was compared to that of compound in the absence of any inhibitor (p value <0.05) Data reported is the mean ± S.D. (n = 3). doi:10.1371/journal.pone.0095024.g004
The resultant supernatant (30 μL ACN to precipitate the plasma proteins was prepared in phosphate buffered saline (PBS). Compounds (300 μL) were mixed with 300 μL of the plasma, prewarmed at 37°C and incubated at 37°C with shaking. Samples (50 μL) were collected prior to the collection of blood samples. Plasma was isolated from fresh-heparin treated blood by centrifugation at 660 × g for 15 min. A 1 mg/mL solution of each test compound (enkephalin, Gal-Enk, Lac-Enk, and Gal-Lac-Enk) was prepared in phosphate buffered saline (PBS). Compounds (300 μL) were mixed with 300 μL of the plasma, prewarmed at 37°C and incubated at 37°C with shaking. Samples (50 μL) were collected at predetermined time points (0, 5, 10, 20, 30, 40, 60, 90 and 120 min), and added into 75 μL ACN to precipitate the plasma proteins. Samples were then centrifuged at 7300 × g for 10 min. The resultant supernatant (30 μL) was analyzed by analytical RP-HPLC for the amount of test compound remaining in the solution using an elution gradient of 20–35% (enkephalin) or 0–70% (glycosylated enkephalins) to compute the kinetic analysis.

### Plasma Stability Assay

Blood sample collection from a healthy and consenting human adult for this study was approved by and conducted according to the guidelines set by The University of Queensland Medical Research Ethics Committee (approval number: 2009000661). Written consent was obtained prior to the collection of blood samples from volunteers. The sample collection was performed in the morning (06:00 to 08:00) after an overnight fast (12 h). Blood samples were obtained from the antecubital vein of healthy (non-smoking, non-diabetic) volunteers, with the consent of each subject. The plasma was separated by centrifugation and stored at −80°C until analysis. The guidelines set by The University of Queensland Medical Research Ethics Committee (approval number: 2009000661). Written consent was obtained prior to the collection of blood samples from volunteers. The sample collection was performed in the morning (06:00 to 08:00) after an overnight fast (12 h). Blood samples were obtained from the antecubital vein of healthy (non-smoking, non-diabetic) volunteers, with the consent of each subject. The plasma was separated by centrifugation and stored at −80°C until analysis.

### Caco-2 Cell Permeability Assay

Caco-2 cells cultured for 21 to 28 days were washed 3 times with 5 mL of 0.02% ethylenediaminetetraacetic acid solution. They were detached using a cell scraper and re-suspended in 4 mL of Hank’s buffered salt solution (HBSS) buffered with 25 mM HEPES to pH 7.4 (HBSS–HEPES). Cells were lysed by sonication of Hank’s buffered salt solution (HBSS) buffered with 25 mM HEPES to pH 7.4 (HBSS–HEPES). Cells were lysed by sonication of 100 μL of the cell homogenate in a TPP 96-well plate and incubated at 37°C with shaking. Each compound was tested in triplicate at 5, 10, 20, 30, 40, 50, 60 and 90 minutes. At each time point, 10 μL of sample was mixed with ACN/water solution containing 5.5% TFA to stop enzymatic degradation. Collected samples were analyzed using LC-MS in positive ion electrospray mode and selective ion monitoring. A Phenomenex Luna C18 column with a linear gradient of 0–80% solvent B was used for enkephalin and a linear gradient of 0–70% solvent B for all other compounds over 5.5 min at a 0.5 mL/min flow rate. A standard curve was generated for each compound and used to calculate the compound’s concentration.

### Caco-2 Cell Stability Assay

Caco-2 cells cultured for 21 to 28 days were washed 3 times with 5 mL of 0.02% ethylenediaminetetraacetic acid solution. They were detached using a cell scraper and re-suspended in 4 mL of Hank’s buffered salt solution (HBSS) buffered with 25 mM HEPES to pH 7.4 (HBSS–HEPES). Cells were lysed by sonication of Hank’s buffered salt solution (HBSS) buffered with 25 mM HEPES to pH 7.4 (HBSS–HEPES). Cells were lysed by sonication on a Branson Sonifier, four times for 5 sec, with an output of 2 and 20% duty cycle. The cell lysate was then centrifuged at 430 × g for 5 minutes to remove cell debris. The protein content of the supernatant was determined using the BioRad protein assay (Gibbons et al. 1990) and adjusted to 0.5–0.8 mg/mL with HBSS–HEPES. The test compounds were solubilized in HBSS–HEPES buffer and 100 μL samples (100 μM) were mixed with 100 μL of the Caco-2 cell homogenate in a TPP 96-well plate and incubated at 37°C with shaking. Each compound was tested in triplicate at 5, 10, 20, 30, 40, 50, 60 and 90 minutes. At each time point, 10 μL of sample was mixed with ACN/water solution containing 5.5% TFA to stop enzymatic degradation. Collected samples were analyzed using LC-MS in positive ion electrospray mode and selective ion monitoring. A Phenomenex Luna C18 column with a linear gradient of 0–80% solvent B was used for enkephalin and a linear gradient of 0–70% solvent B for all other compounds over 5.5 min at a 0.5 mL/min flow rate. A standard curve was generated for each compound and used to calculate the compound’s concentration.

### Table 1. The apparent permeability ($P_{app}$) of enkephalin and glycosylated enkephalins, assessed using in vitro Caco-2 cell monolayer experiments (n = 3).

<table>
<thead>
<tr>
<th>Compound</th>
<th>$P_{app}$ ($10^{-7}$ cm/s)</th>
<th>Control (compound only)</th>
<th>Phlorizin</th>
<th>Phloretin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enkephalin</td>
<td>0.31 ± 0.11</td>
<td>0.19 ± 0.19</td>
<td>0.74 ± 0.40</td>
<td></td>
</tr>
<tr>
<td>Gal-Enk</td>
<td>7.98 ± 2.03</td>
<td>11.80 ± 2.76</td>
<td>15.80 ± 7.23</td>
<td></td>
</tr>
<tr>
<td>Lac-Enk</td>
<td>17.20 ± 12.40</td>
<td>7.11 ± 1.45</td>
<td>9.21 ± 0.84</td>
<td></td>
</tr>
<tr>
<td>Gal-Lac-Enk</td>
<td>4.40 ± 1.63</td>
<td>5.61 ± 1.37</td>
<td>7.12 ± 1.37</td>
<td></td>
</tr>
<tr>
<td>D-Galactose</td>
<td>ND</td>
<td>ND</td>
<td>59.7 ± 30.1</td>
<td></td>
</tr>
<tr>
<td>D-Lactose</td>
<td>ND</td>
<td>ND</td>
<td>19.2 ± 3.28</td>
<td></td>
</tr>
</tbody>
</table>

$^{a}$ Kinetics and affinity analysis of enkephalin and glycosylated enkephalins with ASGPR.

### Table 2. Kinetics and affinity analysis of enkephalin and glycosylated enkephalins with ASGPR.$^{a}$

<table>
<thead>
<tr>
<th>Compound</th>
<th>$K_{on}$ (1/M.s)</th>
<th>$K_{off}$ (1/s)</th>
<th>$K_D$ (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enkephalin</td>
<td>349.7 ± 69.8</td>
<td>0.070 ± 0.0290</td>
<td>277.4 ± 96.0</td>
</tr>
<tr>
<td>Gal-Enk</td>
<td>328.3 ± 84.8</td>
<td>0.0720 ± 0.0250</td>
<td>219.3 ± 164.0</td>
</tr>
<tr>
<td>Lac-Enk</td>
<td>40.7 ± 6.3</td>
<td>0.0086 ± 0.002</td>
<td>211.3 ± 70.9</td>
</tr>
<tr>
<td>Gal-Lac-Enk</td>
<td>45.0 ± 28.9</td>
<td>0.0041 ± 0.003</td>
<td>91.1 ± 22.1</td>
</tr>
<tr>
<td>D-Galactose</td>
<td>ND</td>
<td>ND</td>
<td>59.7 ± 30.1</td>
</tr>
<tr>
<td>D-Lactose</td>
<td>ND</td>
<td>ND</td>
<td>19.2 ± 3.28</td>
</tr>
</tbody>
</table>

$^{a}$ND: Kinetics values for D-galactose and D-lactose could not be uniquely determined due to size differences between the analyte (ASGPR, 37 kDa) and the ligand (D-galactose and D-lactose 180 and 342 Da, respectively) resulting in small RU values and larger than acceptable Chi² values for the kinetic analysis. Calculation of affinity was not affected.

doi:10.1371/journal.pone.0095024.t001
monolayers were washed with pre-warmed HBSS–HEPES and incubated for 30 min at 37°C. Test compounds and the control propanolol, were prepared in HBSS–HEPES buffer to a final concentration of 200 μM. After incubation, buffer in the apical chamber was removed and replaced with 100 μL aliquots of each of the test compounds. At selected time points (30, 90, 120, and 150 min) 0.4 mL of buffer was collected from the basolateral chambers and replaced with the same volume of buffer. The concentration of the peptide in the collected samples was determined using liquid scintillation counting (Liquid Scintillation). Radioactivity of the [14C]-D-mannitol samples was measured using a liquid scintillation counter (Liqui Scintillation Systems).

The apparent permeability ($P_{app}$, cm/s) of each compound was calculated using the following equation:

$$P_{app} = \frac{dC}{dt} \times \frac{Vr}{(A \times C0)}$$

Where $dC/dt$ is the steady-state rate of change in the test item concentration (M/s) or radiochemical concentration (dpm mL/s) in the receiver chamber, $Vr$ is the volume of the receiver chamber (mL), $A$ is the surface area of the cell monolayers and $C0$ is the initial concentration in the donor chamber (M or dpm/mL).

Permeability experiments (as described above) were conducted to investigate whether the compounds used the sugar transporters SGLT1 or GLUT2 for their transport across cell membranes. Samples containing 200 μM test compound and 100 μM phlorizin (inhibitor for SGLT1) or 100 μM phloretin (inhibitor for GLUT2) in HBSS-HEPES buffer were added to the apical chamber. Solution (0.4 mL) was collected from the basolateral chambers and replaced with the same volume of buffer after 30, 90, 120, and 150 min incubations. $P_{app}$ values for each compound were then calculated as above.

The average $P_{app}$ values (±S.D.) from three replicates is presented. Unpaired t-tests ($p<0.05$) were performed using Prism software (Version 6, Graphpad Software Inc., La Jolla, USA) to determine whether the $P_{app}$ values between different compounds were statistically significant.

**SPR Analysis of ASGPR Binding**

The affinities of enkephalin derivatives for ASGPR were tested using SPR methodology on a Biacore T100 at 25°C. Recombinant human ASGPR was immobilized onto a series S sensor chip CM5 using the NHS capture kit, where ASGPR was covalently linked to the surface of the chip via amine groups. Compounds were tested at 10–1000 μM concentrations using multi-cycle kinetics with at least three experiments performed for each interaction. Single cycle kinetics was applied to optimize concentrations prior to completion of multi-cycle kinetics as described by Dumont et al. [36]. D-Galactose and D-lactose at the same concentrations as the test compound were used as positive controls. The running buffer for all SPR experiments was 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl₂, and 0.005% Tween 20.

**Molecular Modeling Studies Using MolDock**

The chemo-enzymatic synthesis of Gal-Lac-Enk was previously conducted using the lipopolysaccharidyl galactosyltransferase LgtC with UDP-Gal as a donor [35]. However, the high cost of UDP-Gal limited the large-scale use of this reaction (despite its high efficiency). On the other hand, UDP-Glc is available for a lower cost and is readily converted to UDP-Gal by galactose epimerase (Figure 1). Previous studies successfully used galactose epimerase for the synthesis of UDP-Gal from UDP-Glc for other one-pot reactions [40–42]. A similar one-pot synthesis of Gal-Lac-Enk was attempted with UDP-Glc and galactose epimerase to synthesize UDP-Gal, which in turn acted as a donor for the LgtC-catalyzed transfer of a galactose unit to Lac-Enk to produce Gal-Lac-Enk (Figure 1). Reaction progress was monitored by RP-HPLC and ES-MS (Figure 2), which showed product formation in the reaction catalyzed by galactose epimerase and LgtC after 48 hrs of incubation at 37°C. The control reaction using UDP-Glc and LgtC only (without galactose epimerase) did not show any product formation.

**Results and Discussion**

**Chemo-enzymatic Synthesis of Enkephalin and its Glycosylated Derivatives**

Enkephalin is susceptible to degradation by enzymes such as aminopeptidases, carboxypeptidases and endopeptidases, leading to rapid degradation in vivo [43,44]. In this study, we used human plasma and Caco-2 cells to test the stability of the glycosylated enkephalins. Plasma stability experiments were conducted to determine the stability of the compounds upon entry into the circulatory system. Compounds with low plasma stability generally showed rapid clearance and consequently low efficacy in vivo [45]. Caco-2 cells are derived from human carcinoma cells and have been used to assess enzymatic stability upon oral or systemic delivery [46]. Our results from plasma and Caco-2 stability experiments showed that enkephalin had a half-life of 2.1 min and 7.1 min, respectively. These values are similar to previously reported values for enkephalin [47,48]. In contrast, the glycosylated enkephalins were considerably more stable. Around 60, 70 and 100% of Gal-Enk, Lac-Enk and Gal-Lac-Enk, respectively, remained in human plasma even after incubation at 37°C for 120 min (Figure 3A). The stability profiles of the glycopeptides (Gal-Enk and Lac-Enk) plateaued after a 40 min incubation in human plasma. This is most likely to have occurred because the test compounds saturated the peptidases found in plasma. The saturation effect was observed for the glycosylated enkephalins.
even when a lower concentration of test compound (0.3 mg/mL) was used (data not shown). We were therefore unable to obtain an accurate measure of the half-life of glycosylated enkephalins in plasma. In Caco-2 cell homogenates, the glycosylated compounds remained stable throughout the course of the experiment (Figure 3B). The increased stability observed for the glycosylated peptides over the parent peptide can be attributed to increased protection of the peptide from enzymes such as aminopeptidase. It is likely that the presence of the carbohydrate moiety sterically hindered the peptidases from accessing the enkephalin peptide. Peptides such as endomorphin [11], luteinizing hormone-releasing hormone [16] and enkephalin modified at the N-terminus [48], also showed a greatly increased stability in comparison to the parent peptides in vitro. For example, Wang et al. [48] observed that the modification of the N-terminus of enkephalin with a lipidic moiety increased the half-life of the parent peptide from 6.7 min to ~193 hrs.

**Permeability of Carbohydrate-modified Enkephalins**

The permeability of enkephalin and glycosylated enkephalins was determined in vitro using Caco-2 cells. The apparent permeability of the negative control 14C mannitol was 4.4×10⁻⁶ (±3.86) cm/s and the apparent permeability for the positive control propanolol was 1.34×10⁻⁴ (±0.009) cm/s.

Enkephalin displayed an apparent permeability of 3.1×10⁻⁶ (±1.1) cm/s. The presence of a mono- or a tri-saccharide moiety in the glycosylated enkephalin structure increased the apparent permeability of enkephalin by 28 and 14 fold, respectively (p < 0.05, Figure 4A, Table 1). The permeability of Lac-Enk (P_{app} 1.72×10⁻⁶ (±1.24) cm/s) was also higher than that of enkephalin alone. However, this increase was not statistically significant due to the high standard deviation observed for the Lac-Enk sample (Figure 4A). Although all the glycosylated enkephalins were more permeable than the parent peptide, we did not observe any significant difference between them. Wong et al. [12] reported that enkephalin was degraded on the apical side of the cells in Caco-2 permeability experiments and consequently reduced the apparent permeability of the compound. The increased permeability of glycosylated enkephalins may result from their increased metabolic stability (Table 1).

The higher permeability observed for the glycosylated enkephalins could also be due to improved transport across the Caco-2 cell membrane. The compounds may be transported into cells via passive diffusion, transporter molecules or by transcytosis. Some reports showed that small glycosylated peptides moved across the cell membrane via sugar transporters [21]. Transport by absorptive transcytosis was also suggested for glycosylated opioid peptides such as enkephalin [18,49]. The apparent permeability of these compounds was measured in the presence of SGLT1 and GLUT2 sugar transport inhibitors; phlorizin and phloretin, respectively [23,50–52], to test if the carbohydrate-derivated enkephalins were able to utilize sugar transporters to enter cells. Our experiments demonstrated that none of the glycosylated enkephalins were inhibited either by phlorizin or phloretin (Table 1, and Figure 4B) suggesting that transport across membranes was not mediated by SGLT1 or GLUT2. Absorptive transport is therefore the most likely mechanism by which the carbohydrate-derivated enkephalin compounds crossed the membrane.

**SPR Experiments to Determine Binding between ASGPR and Enkephalin Derivatives**

Peptide glycosylation could facilitate their binding to specific carbohydrate receptors [17,22]. All of our glycosylated products contained a terminal galactose moiety making them potential targets for the lectin receptor, ASGPR. SPR experiments with ASGPR protein immobilized onto the sensor chip were performed to test whether the glycosylated enkephalins could bind to ASGPR. D-Galactose and D-lactose were used as controls to show that ASGPR could actively bind its native substrate while bound to the sensor chip. Enkephalin, Gal-Enk, and Lac-Enk showed similar binding to ASGPR with K_D values of ~200 μM (Table 2). Our results indicated that the increasing length of the glycan residue resulted in higher binding affinity to the receptor. Consequently, Gal-Lac-Enk, which contained a tri saccharide moiety, displayed a two-fold increase in binding affinity (K_D 91.1 μM) compared to the binding affinity of the peptide alone. The interaction kinetics was measured to confirm that binding to ASGPR was biologically relevant. Kinetic analysis demonstrated that enkephalin modified with longer glycan chains (Lac-Enk and Gal-Lac-Enk) had a slower on-rate (K_on) and a slower off-rate (K_off) (Table 2). However, the off-rate of Lac-Enk for dissociating from ASGPR was twice that of Gal-Lac-Enk resulting in the lower affinity (K_D 211.3 μM) reported for Lac-Enk. This indicated that it took longer for Gal-Lac-Enk to enter the binding pocket of ASGPR but once Gal-Lac-Enk was bound it was more stable than Lac-Enk, Gal-Enk, or enkephalin. Together the data suggested that only Gal-Lac-Enk binding to ASGPR was biologically relevant and therefore glycosylation of enkephalin with at least a tri saccharide moiety was necessary to achieve effective ASGPR binding.

**Molecular Modeling Studies for Enkephalin Derivatives**

We also conducted molecular modeling experiments for the enkephalin derivatives using the crystal structure of ASGPR (PDB 1DV8, [33]). The molecular docking scores obtained showed a good correlation to the surface plasmon resonance data (Table 2). Enkephalin, Gal-Enk and Lac-Enk showed very low binding affinities to the active site of ASGPR with positive MolDock scores (Table 3). However, Gal-Lac-Enk bound to ASGPR with a lower total interaction energy (a negative docking score of −9 kcal/mol) indicating a higher binding affinity to the receptor (Table 3).

The similar outcomes from both the SPR experiment and the molecular modeling studies indicated that the attachment of enkephalin most likely hindered the terminal galactose moiety on Gal-Enk and Lac-Enk from accessing the active site of ASGPR. In the case of Gal-Lac-Enk that contained a tri saccharide moiety, the greater distance between peptide and the terminal galactose enabled binding to the active site of the receptor (Figure 5 and 6).

**Conclusions**

We successfully used a one-pot enzymatic reaction that contained UDP-Glc, galactose epimerase and LgtC galactosyltransferase to galactosylate Lac-Enk to Gal-Lac-Enk. In comparison to the parent peptide, all chemo-enzymatically glycosylated enkephalins showed improved stability and permeability in vitro. The interaction between the glycosylated enkephalins and the carbohydrate receptor ASGPR was examined by SPR experiments and molecular modeling analysis. The SPR systems are widely used as a standard tool in areas such as pharmaceutical drug discovery. Here, SPR in conjunction with molecular modeling, allowed the rapid in vitro evaluation of glycosylated peptide-receptor interactions. The SPR results showed that the addition of a glycan moiety to the enkephalin peptide enabled binding of the peptide to ASGPR. The binding affinity between ASGPR and glycosylated enkephalins increased when the number
Figure 5. Docking between Gal-Lac-Enk and the ASGPR receptor. A) Cartoon representation of Gal-Lac-Enk with the highest negative docking score conformation, in the active site of ASGPR. B) Surface view of ASGPR with Gal-Lac-Enk, docked into the active site. For clarity, atoms have been colored as follows: blue-nitrogen, red-oxygen, gray-carbon, green-Ca$^{2+}$ (on ASGPR) and pink-carbon (on Gal-Lac-Enk). doi:10.1371/journal.pone.0095024.g005
of sugar moieties increased from one (Gal) to three (Gal-Lac). The molecular docking analysis also showed the binding of a trisaccharide (Gal-Lac) modified enkephalin to the active site of ASGPR. The chemo-enzymatic conjugation of oligosaccharides to therapeutic peptides can potentially be applied to cell-specific targeting via carbohydrate receptors. However, further experiments, including in vivo experiments will be required to confirm this observation. Given the wide array of glycosyltransferases available, we envisage that this technique may also be more widely applied to modify therapeutic peptides to contain different oligosaccharide moieties for targeting other carbohydrate receptors.

Author Contributions
Conceived and designed the experiments: MPC PS FE-CJ WMH MFMR LEH-T CJD MPJ IT. Performed the experiments: MPC PS FE-CJ WMH MFMR. Analyzed the data: MPC PS FE-CJ WMH MFMR LEH-T CJD MPJ IT. Contributed reagents/materials/analysis tools: MPC PS FE-CJ WMH MFMR LEH-T CJD MPJ IT. Wrote the paper: MPC PS FE-CJ WMH MFMR LEH-T CJD MPJ IT.

References


